Market›Health Care›Pharmaceuticals›Pharmaceuticals
BELITE BIO INC ADR

BLTE

$161.26Apr 29, 2022 – Apr 24, 2026
Health CarePharmaceuticals$7.23B
MVM
+$169.5M
TD Variance
0.226

Every news event mapped to its market reaction — 65 events, 49 months of data. No predictions, just what happened.

PositiveNegativeNo data· Dot size = magnitude · Scroll to zoom · Drag to pan
Hover to inspect

Want the full written briefing?

The chart shows what moved — the briefing shows why. Sourced, dated, no hot takes.

Subscribe on Substack →

News Events

DateReturnCategorySourceHeadline
2026-03-02-11.0%earningsSeeking AlphaBelite Bio Non-GAAP EPS of -$0.19 beats by $0.38
2025-12-01+10.0%newsSeeking AlphaBelite Bio announces proposed underwritten public offering of ADSs
2025-12-01+10.0%newsSeeking AlphaBelite Bio, Inc (BLTE) Discusses Positive Topline Results from Phase III DRAGON Trial of Tinlarebant in Stargardt Disease Transcript
2025-12-01+10.0%newsInvesting.comBelite Bio stock falls after announcing public offering of ADSs - Investing.com
2025-12-01+10.0%newsTipRanksBelite Bio Shares Dip Despite Promising Trial Results - TipRanks
2025-05-14+9.5%earningsSeeking AlphaBelite Bio GAAP EPS of -$0.27 beats by $0.08
2024-03-26-9.4%newsCNNsymbol__ Stock Quote Price and Forecast - CNN
2026-03-31+8.4%newsGlobeNewswireBelite Bio Announces Availability of Annual Report on Form 20-F Through Company Website
2026-03-31+8.4%newsSeeking AlphaBelite Bio reports FY results
2026-03-31+8.4%newsTipRanksBelite Bio Posts 2025 Form 20-F Annual Report Online as Late-Stage Retinal Drug Trials Advance - TipRanks
2025-11-10-8.4%legalSeeking AlphaBelite Bio outlines regulatory path and $275.6M cash position while preparing for Tinlarebant commercialization
2025-11-10-8.4%earningsSeeking AlphaBelite Bio, Inc (BLTE) Q3 2025 Earnings Call Transcript
2025-11-10-8.4%earningsSeeking AlphaBelite Bio GAAP EPS of -$0.28 beats by $0.20
2025-11-10-8.4%earningsSeeking AlphaBelite Bio GAAP EPS of -$0.28
2023-08-24+8.3%analystZacks Investment ResearchWhat is the current Price Target and Forecast for Belite Bio (BLTE) - Zacks Investment Research
2025-11-12+7.9%earningsSeeking AlphaBelite Bio, Inc 2025 Q3 - Results - Earnings Call Presentation
2026-04-23-4.1%newsGlobeNewswireInternational companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on April 28, 2026
2026-04-23-4.1%newsGlobeNewswireBelite Bio to Participate in Four Upcoming Investor Conferences
2026-04-23-4.1%newsStock TitanFour Belite Bio conference appearances are set from April 28 to May 26 - Stock Titan
2026-04-23-4.1%newsSahmIs Tinlarebant’s Rolling NDA for Stargardt Disease Altering The Investment Case For Belite Bio (BLTE)? - Sahm
2025-11-24+3.6%newsBenzingaAlibaba, Oscar Health, Ondas Holdings, Lumentum, Tesla And Other Big Stocks Moving Higher On Monday - Benzinga
2025-05-15+3.4%newsSeeking AlphaBelite Bio: Investors Face Tricky Decision Ahead Of Key STGD1 Study Readout
2025-05-15+3.4%earningsSeeking AlphaBelite Bio signals positive DSMB review and targets 500-patient PHOENIX trial enrollment completion in Q3 2025 while maintaining strong cash runway
2025-05-15+3.4%earningsSeeking AlphaBelite Bio, Inc (BLTE) Q1 2025 Earnings Call Transcript
2026-04-16-3.4%earningsMarketBeatBelite Bio (NASDAQ:BLTE) Shares Down 5.1% - Here's What Happened - MarketBeat
2025-08-11+3.2%earningsSeeking AlphaBelite Bio GAAP EPS of -$0.50 misses by $0.09
2026-03-10-2.7%newsMarketBeatBelite Bio Details Phase 3 DRAGON Win as Tinlarebant Cuts Stargardt Lesion Growth 36% at Conference
2026-04-13-2.7%earningsSimply Wall St.When Can We Expect A Profit From Belite Bio, Inc (NASDAQ:BLTE)?
2026-04-13-2.7%earningsMarketBeatWan-Shan Chen Sells 1,100 Shares of Belite Bio (NASDAQ:BLTE) Stock - MarketBeat
2026-04-13-2.7%earningsMarketBeatInsider Selling: Belite Bio (NASDAQ:BLTE) CFO Sells 6,200 Shares of Stock - MarketBeat
2026-04-13-2.7%analystInvesting.com South AfricaH.C. Wainwright reiterates Belite Bio stock rating at buy By Investing.com - Investing.com South Africa
2026-03-04+2.6%analystTipRanksBelite Bio price target raised to $266 from $200 at Cantor Fitzgerald
2026-03-04+2.6%earningsSeeking AlphaBelite Bio, Inc 2025 Q4 - Results - Earnings Call Presentation
2026-03-30+2.3%earningsMarketBeatShort Interest in Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Grows By 25.1% - MarketBeat
2025-08-07+2.1%newsSeeking AlphaBelite Bio announces registered direct offering of $15 million
2025-12-02-2.0%newsSeeking AlphaBelite Bio prices 2.27M ADSs at $154.00 to raise $350M in public offering
2025-12-02-2.0%newsTipRanksWhy Belite Bio’s Stock is Making Waves - TipRanks
2026-04-07+1.8%analystInvesting.comBenchmark reaffirms Belite Bio stock rating on cash position, trial progress - Investing.com
2026-04-02+1.8%newsThe Globe and MailBelite Bio Faces Higher Compliance Burden as It Becomes a Large Accelerated Filer, Raising Costs and Operational Risk - The Globe and Mail
2025-03-17+1.7%earningsSeeking AlphaBelite Bio, Inc. (BLTE) Q4 2024 Earnings Call Transcript
2025-03-17+1.7%earningsSeeking AlphaBelite Bio GAAP EPS of -$0.32 misses by $0.01
2026-01-27+1.6%earningsSeeking AlphaBelite Bio On A Tear As It Approaches Key Regulatory Submissions
2026-01-27+1.6%newsTipRanksBelite Bio Completes Global Enrollment in DRAGON II Tinlarebant Trial for Stargardt Disease - TipRanks
2025-08-12+1.6%earningsSeeking AlphaBelite Bio, Inc 2025 Q2 - Results - Earnings Call Presentation
2025-08-12+1.6%earningsSeeking AlphaBelite Bio targets NDA submission for Tinlarebant in first half of 2026 amid strong cash runway and Phase III progress
2025-08-12+1.6%earningsSeeking AlphaBelite Bio, Inc (BLTE) Q2 2025 Earnings Call Transcript
2025-05-21+1.4%legalSeeking AlphaBelite Bio gets FDA breakthrough therapy status for Stargardt disease treatment
2026-03-17-1.3%newsTipRanksBelite Bio Stock Stumbles as Traders Flee Rally - TipRanks
2026-01-28+1.2%analystInvesting.comH.C. Wainwright reiterates Buy rating on Belite Bio stock with $185 target - Investing.com
2026-04-22-1.1%newsGlobeNewswireBelite Bio to Present at the Deutsche Bank American Depositary Receipt Virtual Investor Conference on April 28th
2025-11-04+0.9%newsSeeking AlphaBelite Bio, Inc (BLTE) Presents at Deutsche Bank ADR Virtual Investor Conference 2025 Prepared Remarks Transcript
2025-11-04+0.9%newsSeeking AlphaBelite Bio, Inc (BLTE) Presents at Deutsche Bank ADR Virtual Investor Conference 2025 - Slideshow
2026-04-21+0.9%earningsGlobeNewswireBelite Bio Initiates Rolling Submission of New Drug Application to the U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease
2026-04-21+0.9%earningsMarketBeatBelite Bio (NASDAQ:BLTE) Insider Nathan Mata Sells 1,000 Shares - MarketBeat
2026-04-21+0.9%legalTipRanksBelite Bio Starts FDA Rolling NDA for Tinlarebant in Stargardt Disease - TipRanks
2022-06-20+0.7%newsTradingViewBLTE Stock Price and Chart — NASDAQ:BLTE - TradingView
2026-04-06-0.6%earningsMarketBeatBelite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
2026-03-03+0.3%legalSimply Wall St.Belite Bio Advances Tinlarebant Toward FDA Review After DRAGON Success
2026-03-03+0.3%earningsSeeking AlphaBelite Bio targets Q2 2026 NDA submission and $200M–$250M commercialization spend for Stargardt therapy while cash reserves surge
2026-03-03+0.3%earningsSeeking AlphaBelite Bio, Inc (BLTE) Q4 2025 Earnings Call Transcript
2026-02-11+0.3%newsSeeking AlphaBelite Bio, Inc (BLTE) Presents at 41st Asia-Pacific Academy of Ophthalmology Congress (APAO) - Slideshow
2022-06-02-0.2%earningsMarketBeatBelite Bio (BLTE) Short Interest & Short Float | Updated Apr 2026 $BLTE - MarketBeat
2025-12-03-0.1%newsSeeking AlphaBelite Bio, Inc (BLTE) Discusses Positive Topline Results from Phase III DRAGON Trial of Tinlarebant in Stargardt Disease - Slideshow
2026-04-24—legalSimply Wall St.How Belite Bio’s (BLTE) Rolling FDA NDA For Tinlarebant Has Changed Its Investment Story
2022-04-29—newsChartMillBLTE Stock Price, Quote & Chart | BELITE BIO INC - ADR (NASDAQ:BLTE) - ChartMill
tickerdossier.comtickerdossier.substack.com